Navigation Links
Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement
Date:12/14/2009

BRAINTREE, Mass., Dec. 14 /PRNewswire-FirstCall/ -- Haemonetics Corporation (NYSE: HAE) announced today that it has filed a new legal action to stop Fenwal Inc.'s continued patent infringement resulting from Fenwal's just released red cell collection kits, using a modified separation chamber. Fenwal allegedly modified its separation chamber to circumvent Haemonetics' patent and the injunction entered by the Court prohibiting Fenwal's continued sale of infringing products after December 1, 2010. According to statements made by Fenwal's counsel today in the United States District Court, Fenwal is determined to proceed with commercialization without 510(k) clearance from the U.S. Food & Drug Administration.

On December 7, 2009 Fenwal announced that it began shipping a red cell collection kit with a modified separation chamber, and that it is discontinuing sales of its original kit. Ten months ago, on January 31, 2009, a federal jury had determined that Fenwal's original collection kit infringes a Haemonetics patent, and found Fenwal liable to Haemonetics for over $15 million in damages. The United States District Court for the District of Massachusetts later added millions of dollars in pre-judgment interest and ordered the product removed from the market by December 1, 2010. The District Court also ordered that between January 31, 2009 and December 1, 2010, Fenwal must pay Haemonetics a 10% royalty on the offending product's sales. The damages have not been paid, and the royalties are being escrowed pending decision on Fenwal's appeal to the United States Court of Appeals for the Federal Circuit. A decision by the appellate court is not expected before late 2010 at the earliest.

Haemonetics filed a new lawsuit against Fenwal on account of the modified collection kit, requesting another jury trial that seeks multiple damages for willful infringement, and a permanent injunction. The new matter has been assigned to the same federal judge who issued the permanent injunction on Fenwal's original red cell kit.

Brian Concannon, Haemonetics' President and CEO said, "We commit to supporting blood collectors who wish to assure an orderly transition away from infringing product well in advance of the December 2010 injunction. It is our genuine desire to protect customers from involvement in this commercial dispute between competitors. As we continue to make multi million dollar investments to bring new technologies and blood management offerings to the blood community, we are likewise committed to protect our intellectual property, which is the foundation of the business we've built."

Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing innovative blood management solutions for our customers. Together, our devices and consumables, information technology platforms, and consulting services deliver a suite of business solutions to help our customers improve clinical outcomes and reduce the cost of healthcare for blood collectors, hospitals, and patients around the world. Our technologies address important medical markets: blood and plasma component collection, the surgical suite, and hospital transfusion services. To learn more about Haemonetics, visit our web site at http://www.haemonetics.com .


    CONTACT:
    Julie Fallon
    Tel. (781) 356-9517
    Alternate Tel. (617) 320-2401
    fallon@haemonetics.com

SOURCE Haemonetics Corporation


'/>"/>
SOURCE Haemonetics Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Haemonetics Sets Date for Second Quarter Fiscal Year 2010 Earnings Release: November 2, 2009
2. Haemonetics Signs Comprehensive Agreement with Blood Centers of America
3. Haemonetics Expands Its Blood Management Product Portfolio with Acquisition of SEBRA Business Unit
4. Haemonetics Sets Date for First Quarter Fiscal Year 2010 Earnings Release: August 3, 2009
5. Haemonetics Shares Success of Outstanding Fiscal 2009 Performance with Employees
6. Haemonetics Sets Date For Fourth Quarter Fiscal Year 2009 Earnings Release: May 4, 2009
7. Haemonetics Sets Date for Investor/Analyst Meeting
8. Haemonetics Expands Its Blood Management Leadership With Acquisition of Neoteric Technology Ltd
9. Haemonetics Announces Change to Board of Directors
10. Haemonetics Bolsters Blood Bank Information Management Portfolio With Acquisition of Altivation Software
11. Haemonetics Reports Double Digit Growth in Revenue, Operating Income, and EPS for the Third Quarter Fiscal 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... ... today the continuation of the ‘Pay It Forward’ program into 2016. BioPlus partners ... at our specialty pharmacy. , “Since our Pay It Forward program began, ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Boston Store, Carson’s, Elder-Beerman, Herberger’s and Younkers department stores, announced it has raised ... of Wisconsin Cancer Center, Holden Comprehensive Cancer Center at the University of Iowa, ...
(Date:2/9/2016)... ... February 09, 2016 , ... IsoComforter, Inc., ... introduction of the newly designed, innovative shoulder wrap. The newly designed shoulder ... for the injured arm and shoulder to promote faster healing. It is highly ...
(Date:2/9/2016)... ... , ... i2i Systems, an early innovator and developer of population health management ... KLAS report, Population Health Management 2015: How Far Can Your Vendor Take You? ... (PHM). The latest KLAS Report, leveraging over 200 user interviews, shines a light ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... its newly redesigned website, federallabs.org . The site houses a wealth of ... available federal technologies through the process called technology transfer (T2). As a network ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Axovant Sciences Ltd. (NYSE:  AXON), a leading ... dementia, today announced further details of three new ... aspects of Lewy body dementia, a disease affecting ... out of the three studies were recently initiated ... this quarter. In addition, the Company reported financial ...
(Date:2/9/2016)... SAN FRANCISCO , February 9, 2016 ... a biotechnology company focused on developing products for Regenerative ... will be a featured presenting company at Source Capital ... place on February 10-11, 2016 in New ... given on Wednesday, February 10, 2016 at 12:30 pm ...
(Date:2/9/2016)... -- The global prefilled syringes market accounted for $3,905.1 ... grow with a CAGR of 12.9% during 2015-2020. Among ... the global prefilled syringes market, with 90.1% share in ... The global market of prefilled syringes is up surging ... increasing demand for vaccines, increasing prevalence of chronic and ...
Breaking Medicine Technology: